undamentalytics Newsletter
Sign in

Eyepoint, Inc. revenue

Eyepoint, Inc.'s revenue was $31.4m in fiscal 2025, down 27.5% on the year before. Since fiscal 2010 ($23.1m) it has grown at a compound 2.1% a year. Over the last twelve months it was $2.8m.

Revenue history

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2010Jun 20102011Jun 20112012Jun 20122013Jun 20132014Jun 20142015Jun 20152016Jun 20162017Jun 20172018Jun 20182019Dec 20192020Dec 20202021Dec 20212022Dec 20222023Dec 20232024Dec 20242025Dec 2025LTMJun 2026
Revenue23542327283203437414643313
Growth on the year before—−78.5%−29.0%−39.2%+62.1%+664.9%−93.9%+365.4%−60.7%+587.8%+69.1%+7.3%+12.1%+11.1%−6.0%−27.5%—

Revenue as reported in the company's 10-K and 10-Q filings (for banks, net interest income plus non-interest income). Growth is left blank when the earlier figure was zero or negative.

Where the revenue comes from

Fiscal year to December 31, 2025
Products and services
Line of business Revenue YoY
License and Collaboration Agreement $16.7M ▼ 56.5%
Royalty $13M ▲ 708.5%
YUTIQ Product $1.6M ▼ 48.4%
Products $1.6M ▼ 49.6%

These categories overlap or exclude eliminations, so shares aren't shown.

Geography
Region Revenue Share YoY
United States $30M 95.6% ▼ 28.7%
China $1.3M 4.1% ▲ 14.9%
United Kingdom $100,000 0.3% 0.0%

From Eyepoint, Inc.'s 10-K filed March 5, 2026, as tagged in the filing. View filing. Indented rows are part of the line above; their share is of that line. In the bars, the faint bar behind is the year before.

Revenue against peers

Pharmaceuticals: the closest covered companies by revenue. Last twelve months.

CompanyRevenueGrowth3-year growth a year
Eyepoint, Inc. $2.8m -94.6% -57.9%
Therapeuticsmd, Inc. $3.3m 27.8% -63.9%
China Pharma Holdings, Inc. $3.9m -11.0% -21.0%
Nutriband Inc. $1.6m -37.3% -10.8%
Lipocine Inc. $1.6m -62.7% 205.6%
China SXT Pharmaceuticals, Inc. $1.1m -34.6% —

Compare with peers

Head to head: EYPT vs TXMDCPHI vs EYPTEYPT vs NTRB

More: Pharmaceuticals stocks compared, Health Care sector, rankings of US companies

Figures from Eyepoint, Inc.'s SEC filings (10-K and 10-Q), retrieved October 29, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Eyepoint, Inc.